Khalid Alswat
YOU?
Author Swipe
View article: Intermittent fasting and liver disease: Insights from the Ramadan model
Intermittent fasting and liver disease: Insights from the Ramadan model Open
Intermittent fasting (IF) has gained growing interest for its potential metabolic benefits. However, the unique physiological aspects of Ramadan fasting (RF), a culturally and religiously significant form of dry IF, remain underexplored, p…
View article: Hepatitis C Direct-Acting Antivirals in the Immunosuppressed Host: Mechanisms, Interactions, and Clinical Outcomes
Hepatitis C Direct-Acting Antivirals in the Immunosuppressed Host: Mechanisms, Interactions, and Clinical Outcomes Open
Direct-acting antivirals (DAAs) have transformed hepatitis C virus (HCV) management, offering high cure rates, favorable safety, and simplified regimens. Management in immunosuppressed patients remains challenging due to drug–drug interact…
View article: Mapping artificial intelligence adoption in hepatology practice and research: challenges and opportunities in MENA region
Mapping artificial intelligence adoption in hepatology practice and research: challenges and opportunities in MENA region Open
Background Artificial intelligence (AI) is increasingly relevant to hepatology, yet real-world adoption in the Middle East and North Africa (MENA) is uncertain. We assessed awareness, use, perceived value, barriers, and policy priorities a…
View article: Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards
Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards Open
The reclassification of nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) marks a significant shift in understanding liver disease, particularly in Saudi Arabia, where metabolic di…
View article: Mapping Metabolic Dysfunction-associated Steatotic Liver Disease Models of Care across 17 Middle East and North Africa Countries: Insights into Guidelines, Infrastructure, and Referral Systems
Mapping Metabolic Dysfunction-associated Steatotic Liver Disease Models of Care across 17 Middle East and North Africa Countries: Insights into Guidelines, Infrastructure, and Referral Systems Open
Significant policy, structural, and educational gaps persist in MASLD care across the MENA region. To address this rising burden, countries must adopt integrated national strategies, expand access to non-invasive diagnostic tests, institut…
View article: Infection and Metabolic Dysfunction-Associated Steatotic Liver Disease: Two Peas in a Pod
Infection and Metabolic Dysfunction-Associated Steatotic Liver Disease: Two Peas in a Pod Open
Objective Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) is increasingly linked to a heightened risk of various infections, significantly impacting patient health outcomes. This review aims to explore the systemic implica…
View article: Multidisciplinary Team Management of Hepatocellular Carcinoma in the MENA Region: Current Practices, Challenges, and Gaps
Multidisciplinary Team Management of Hepatocellular Carcinoma in the MENA Region: Current Practices, Challenges, and Gaps Open
Our result highlights the pivotal role of MDTs in HCC management in the MENA region, demonstrating adherence to evidence-based guidelines and exposing critical gaps in resource availability, technology integration, and patient-centered dec…
View article: Metabolic Dysfunction‐Associated Steatotic Liver Disease in the <scp>MENA</scp> Region: Setting a Research and Action Priority Agenda
Metabolic Dysfunction‐Associated Steatotic Liver Disease in the <span>MENA</span> Region: Setting a Research and Action Priority Agenda Open
Background & Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a growing health challenge, particularly in Middle East and North Africa (MENA) countries. This study aimed to establish a consensus‐driven research and …
View article: Genetic susceptibility of Saudi Population to Hepatitis B Virus (HBV) infection and the predicted functional consequences
Genetic susceptibility of Saudi Population to Hepatitis B Virus (HBV) infection and the predicted functional consequences Open
Chronic Hepatitis B virus (HBV) infection poses a global public health challenge, for which an effective cure remains elusive. A substantial amount of data has shown that single nucleotide polymorphisms (SNPs) within host genes can affect …
View article: Global Burden of Major Chronic Liver Diseases in 2021
Global Burden of Major Chronic Liver Diseases in 2021 Open
Background This study utilised the Global Burden of Disease data (2010–2021) to analyse the rates and trends in point prevalence, annual incidence and years lived with disability (YLDs) for major chronic liver diseases, such as hepatitis B…
View article: AI-Based Multiclass Grading of Hepatic Steatosis From B-Mode Ultrasound: Generalization Across Modalities and Clinical Comparison With Radiologists
AI-Based Multiclass Grading of Hepatic Steatosis From B-Mode Ultrasound: Generalization Across Modalities and Clinical Comparison With Radiologists Open
Non-alcoholic fatty liver disease (NAFLD) is a growing public health challenge, underscoring the need for scalable, non-invasive tools to grade hepatic steatosis. Although B-mode ultrasound is accessible and safe, its reliability is limite…
View article: Hybrid Deep Learning and Machine Learning for Detecting Hepatocyte Ballooning in Liver Ultrasound Images
Hybrid Deep Learning and Machine Learning for Detecting Hepatocyte Ballooning in Liver Ultrasound Images Open
Background: Hepatocyte ballooning (HB) is a significant histological characteristic linked to the advancement of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Although clinicians now consider liver bio…
View article: Burden of disease attributable to high body mass index: an analysis of data from the Global Burden of Disease Study 2021
Burden of disease attributable to high body mass index: an analysis of data from the Global Burden of Disease Study 2021 Open
National Natural Science Foundation of China and National Key R&D Program of China.
View article: Knowledge about metabolic dysfunction-associated steatotic liver disease among the medical professionals from countries in the MENA region
Knowledge about metabolic dysfunction-associated steatotic liver disease among the medical professionals from countries in the MENA region Open
A knowledge gap in the identification, diagnosis, and management of MASLD/NAFLD was found despite the growing burden of MASLD/NAFLD in Saudi Arabia, Egypt, and Türkiye. Education to increase awareness is needed.
View article: Stigma in steatotic liver disease: A survey of patients from Saudi Arabia
Stigma in steatotic liver disease: A survey of patients from Saudi Arabia Open
Background: A recent name change of nonalcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated fatty liver disease (MAFLD) to metabolic dysfunction-associated steatotic liver disease was primarily driven by potential stig…
View article: Editorial: Emerging therapeutic approaches for non-alcoholic fatty liver disease
Editorial: Emerging therapeutic approaches for non-alcoholic fatty liver disease Open
EDITORIAL article Front. Med., 18 June 2024Sec. Gastroenterology Volume 11 - 2024 | https://doi.org/10.3389/fmed.2024.1437385
View article: Validation of FIB-6 score in assessment of liver fibrosis in chronic hepatitis B
Validation of FIB-6 score in assessment of liver fibrosis in chronic hepatitis B Open
Background: We recently developed a simple novel index called fibrosis 6 (FIB-6) using machine learning data analysis. We aimed to evaluate its performance in the diagnosis of liver fibrosis and cirrhosis in chronic hepatitis B (CHB). Meth…
View article: The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease
The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease Open
Patients with nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD), may experience impaired health-related quality of life and stigmatization. Using a specifically desi…
View article: Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa
Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa Open
Background and Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is common and closely associated with type 2 diabetes (T2D). We assessed the prevalence of NA…
View article: SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024
SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024 Open
Hepatitis C virus (HCV) infection has been a major global health concern, with a significant impact on public health. In recent years, there have been remarkable advancements in our understanding of HCV and the development of novel therape…
View article: The future health and economic burden of obesity-attributable type 2 diabetes and liver disease among the working-age population in Saudi Arabia
The future health and economic burden of obesity-attributable type 2 diabetes and liver disease among the working-age population in Saudi Arabia Open
Background Obesity and type 2 diabetes (T2DM) are increasing in Saudi Arabia (SA). Among other conditions, these risk factors increase the likelihood of non-alcoholic fatty liver disease (NAFLD), which in turn increases risks for advanced …
View article: Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals
Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals Open
BACKGROUND: Clearance of hepatitis C virus (HCV) can potentially slow or reverse liver fibrosis and cirrhosis. Studies of fibrosis changes after treatment with direct-acting antivirals (DAAs) are limited. OBJECTIVES: We aimed to assess the…